Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 2/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800678 | 0.75 | IDO1 (0.41) | METAP2METAP1PDE5AKDM4E | |
| SCHEMBL18099789 | 0.73 | KDM4E (0.50) | EGFRMETAP2METAP1PDE5AKDM4E | |
| SCHEMBL28605609 | 0.68 | KDM4E (0.44) | EGFRKDM4EHTTPOLBRAD52 | |
| SCHEMBL30362637 | 0.68 | ACHE (0.57) | EGFRKDM4EHTTPOLBRAD52 | |
| SCHEMBL28614688 | 0.68 | ACHE (0.57) | EGFRKDM4EHTTPOLBRAD52 | |
| SCHEMBL31719610 | 0.67 | EGFR (0.41) | EGFRKDM4EHTTPOLBRAD52 | |
| SCHEMBL30369441 | 0.67 | EGFR (0.41) | EGFRKDM4EHTTPOLBRAD52 | |
| SCHEMBL1869156 | 0.67 | EGFR (0.41) | EGFRKDM4EHTTPOLBRAD52 | |
| SCHEMBL9431285 | 0.67 | PIK3CG (0.32) | PIK3CG | |
| SCHEMBL10916482 | 0.67 | ESR1 (0.47) | EGFRPIK3CGKDM4EHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232246-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100168384-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168384-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | EGFR 3789/4885PIK3CG 2134/4885METAP2 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.